Rhodanine‐Based Tau Aggregation Inhibitors in Cell Models of Tauopathy

Abstract

Breaking up the crowd: The pathological aggregation of tau protein correlates closely with the progression of Alzheimer's disease. Rhodanine-based inhibitors of tau aggregation (e.g. 1) have been identified, and it has been shown that tau aggregation in a cell model is reversible and can be inhibited by small molecules at nanomolar concentrations (see SEM images). Supporting information for this article is available on the WWW under http://www.wiley-vch.de/contents/jc_2002/2007/z704051_s.pdf or from the author. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.